CRISPR/Cas genome editing in triple negative breast cancer: Current situation and future directions

[Display omitted] Triple negative breast cancer (TNBC) has been well-known to be closely associated with the abnormal expression of both oncogenes and tumor suppressors. Although several pathogenic mutations in TNBC have been identified, the current therapeutic strategy is usually aimed at symptom r...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Biochemical pharmacology 2023-03, Vol.209, p.115449-115449, Article 115449
Hauptverfasser:	Fu, Leilei, Li, Zixiang, Ren, Yueting, Yu, Haiyang, Liu, Bo, Qiu, Yuling
Format:	Artikel
Sprache:	eng
Schlagworte:	Breast cancer Cancer therapy CRISPR-Cas Systems CRISPR/Cas Gene Editing Humans Triple negative breast cancer Triple Negative Breast Neoplasms - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!